abacavir

(redirected from Triumeq)
Also found in: Medical.
Related to Triumeq: Abacavir, Stribild

a·bac·a·vir

 (ə-băk′ə-vîr′)
n.
An antiviral drug, C14H18N6O, that is a nucleoside reverse transcriptor inhibitor and is used in its sulfate form in combination with other drugs for the treatment of HIV infection.

[aba- (perhaps from ab, first two letters of the alphabet, from the fact that it was the first of this type of antiviral developed) + -c(arbocyclic nucleoside), nucleoside whose oxygen in the sugar ring has been replaced by a carbon + a(nti)vir(al) .]
Translations

abacavir

n abacavir m
References in periodicals archive ?
Contract award notice: Establishment of a framework agreement for the supply of triumeq to the penitentiary centers dependent on the sgiipp (spain-madrid: Pharmaceutical products)
HIV sales increased 37% driven primarily by strong performances from both Triumeq, a single-pill treatment combining dolutegravir, abacavir and lamivudine, and Tivicay (dolutegravir), an innovative integrase strand transfer inhibitor.
TABLE 2 DHHS recommended treatment regimens (2) Generic Brand Integrase strand transfer inhibitor-based regimens dolutegravir/abacavir/lamivudine Triumeq dolutegravir + tenofovir disoproxil Tivicay + Truvada or fumarate/-emtricitabine or Descovy tenofovir alafenamide/-emtricitabine elvitegravir/cobicistat/tenofovir Genvoya alafenamide/-emtricitabine elvitegravir/cobicistat/tenofovir disoproxil Stribild fumarate/emtricitabine raltegravir + tenofovir disoproxil Isentress + Truvada or fumarate/-emtricitabine or tenofovir Descovy alafenamide/-emtricitabine Protease inhibitor-based regimens darunavir and ritonavir + tenofovir Prezista and Norvir + disoproxil fumarate/emtricitabine or Truvada or Descovy tenofovir alafenamide/-emtricitabine DHHS, US Department of Health and Human Services.
M2 EQUITYBITES-July 18, 2016-ARIA announces superior efficacy from phase IIIb, open-label, international, multi-centre ARIA study of Triumeq for treatment-naA-ve women with HIV
M2 PHARMA-July 18, 2016-ARIA announces superior efficacy from phase IIIb, open-label, international, multi-centre ARIA study of Triumeq for treatment-naA-ve women with HIV
Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Celsentri, Evotaz, Intelence, Isentress, Stribild, Triumeq, Truvada, and Viread.
The uplift was underpinned by a strong performance from new product sales, rising 20% quarter on quarter to PS821m, driven in part by HIV drugs Tivicay and Triumeq.
The uplift was underpinned by a strong performance from new product sales, rising 20% quarter on quarter to PS821 million, driven in part by HIV drugs Tivicay and Triumeq.
The uplift was underpinned by a strong performance from new product sales, rising 20 per cent quarter on quarter to PS821 million, driven in part by HIV drugs Tivicay and Triumeq.
Under his leadership of Pharmaceuticals R&D, GSK has delivered a number of innovative new medicines to patients in areas including Respiratory, Oncology and HIV: a new portfolio of inhaled respiratory medicines that includes Trelegy, the only once-daily single inhaler triple therapy for COPD; Nucala, a first-in-class biologic therapy for severe asthma; two targeted therapies to treat metastatic melanoma, Tafinlar and Mekinist; and, in HIV, Tivicay and Triumeq.
Respiratory sales grew 5% CER to 1,683 million [pounds sterling], driven by the Ellipta portfolio and Nucala, while HIV sales were up 19% CER to 985 million [pounds sterling], driven by a continued increase in market share for Triumeq and Tivicay.
Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Evotaz, Intelence, Isentress, Selzentry, Stribild, Triumeq, Truvada, and Viread.